Translational activating rnas for SYNGAP1 deficiency treatment

Overview

The University of Chicago presents a groundbreaking biotechnology solution utilizing translation-activating RNAs (taRNAs) to address SYNGAP1 deficiency, a significant genetic cause of intellectual disability accompanied by epilepsy. SYNGAP1 haploinsufficiency presents developmental challenges including autism. Conventional gene therapies lack cell-type specificity, essential for treating conditions like SYNGAP1 deficiency that affects specific neuronal populations. taRNAs offer a precise method to upregulate gene expression selectively in excitatory neurons, potentially revolutionizing treatment for this and related genetic disorders.

Technical specifications

Key features:

• Bifunctional design: taRNAs possess a guide domain complementary to target mRNA and a structural RNA motif derived from IRES elements, facilitating the recruitment of key initiation factors to activate translation.
• Selective activation: Unlike other methods, taRNAs allow for targeted gene expression in specific cell types, crucial for conditions like SYNGAP1 deficiency.
• Preclinical validation: Initial studies demonstrate successful restoration of protein levels in endogenous targets, including SYNGAP1. Ongoing efforts focus on optimizing taRNA designs for potency, stability, and selectivity.
• AAV packaging: Lead taRNAs will be packaged into adeno-associated viruses (AAVs) for efficient delivery in disease-relevant models.

Technology readiness level

This technology is currently at TRL 3, having demonstrated proof of concept and initial validation in controlled environments. Future steps include optimizing taRNA constructs and assessing their efficacy and safety in patient-derived cells and animal models to advance toward clinical applications.